niacin and Atherogenesis studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

Excerpt	Relevance	Reference
"Although studies have reported direct inhibition of inflammatory pathways with niacin, the effect of niacin on arterial wall inflammation remains unknown."	9.20	A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. ( Alavi, A; deGoma, EM; Dunbar, RL; Litt, HI; Mehta, NN; Mohler, ER; Pollan, L; Rader, DJ; Saboury, B; Salavati, A; Schoen, M; Shinohara, RT; Torigian, DA; Woo, J, 2015)
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol."	9.17	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013)
"Fifty patients with the metabolic syndrome (Adult Treatment Panel (ATP) III criteria) were randomised to either extended-release niacin (1000 mg/day) or placebo."	9.12	The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. ( Hammoud, R; Khan, BV; Nagamia, S; Oguchi, A; Thoenes, M; Umpierrez, GE; Vaccari, CS, 2007)
"Niacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes."	8.87	Effects of niacin on atherosclerosis and vascular function. ( Choudhury, RP; Digby, JE; Ruparelia, N, 2011)
"The reader will gain knowledge of the development of niacin as an antiatherosclerosis treatment and of the added value that laropiprant may offer this treatment principle; and also the present place of niacin/laropiprant in the armamentarium of cardiovascular preventive drugs."	8.86	Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. ( Olsson, AG, 2010)
"Niacin has been widely used as an antihyperlipidemic drug, but the flushing effect restricted its clinical application."	7.96	Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. ( Cai, W; Chen, J; Jiang, Y; Jin, M; Liu, P; Pi, R; Yan, J; Yao, M, 2020)
"BACKGROUND Niacin is a broad-spectrum lipid-regulating drug used for the clinical therapy of atherosclerosis; however, the mechanisms by which niacin ameliorates atherosclerosis are not clear."	7.81	Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. ( Guo, L; Huang, C; Liu, H; Shu, L; Su, G; Sun, G; Xu, J; Zhang, J, 2015)
"Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol with modest HDL-cholesterol-raising and additional anti-inflammatory effects."	7.79	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. ( Havekes, LM; Heemskerk, MM; Jukema, JW; Kühnast, S; Louwe, MC; Pieterman, EJ; Princen, HM; Rensen, PC; Smit, JW; van den Berg, SA; van der Hoorn, JW; van Klinken, JB, 2013)
"The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0."	6.80	Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts ( Abdurrahim, G; Banerjee, S; Brilakis, ES; Chao, H; Christopoulos, G; Coleman, A; de Lemos, JA; Guerra, A; Han, H; Kotsia, A; McGuire, DK; Packer, M; Rangan, BV; Roesle, M; Sosa, A; Xu, H, 2015)
"Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin."	5.38	Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. ( Barter, PJ; Chen, K; Rye, KA; Wu, BJ, 2012)
"Niacin has been used for decades to lower the plasma concentrations of cholesterol, free fatty acids, and triglycerides in humans, and in addition it raises more than any other drug the levels of the protective high density lipoprotein."	5.34	Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. ( Yu, BL; Zhao, SP, 2007)
"Although studies have reported direct inhibition of inflammatory pathways with niacin, the effect of niacin on arterial wall inflammation remains unknown."	5.20	A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. ( Alavi, A; deGoma, EM; Dunbar, RL; Litt, HI; Mehta, NN; Mohler, ER; Pollan, L; Rader, DJ; Saboury, B; Salavati, A; Schoen, M; Shinohara, RT; Torigian, DA; Woo, J, 2015)
"In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol."	5.17	Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. ( Anderson, DC; Boden, WE; Chaitman, BR; Cruz-Flores, S; Goldstein, LB; Grant, S; Kostuk, WJ; Padley, RJ; Sila, CA; Teo, KK; Weintraub, WS, 2013)
"To assess effects of niacin on risk factors of atherosclerosis in men with coronary heart disease (CHD) and high lipoprotein(a) [Lp(a)] levels."	5.15	[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. ( Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP, 2011)
"Patients with coronary heart disease (CHD) or CHD equivalent with low-density lipoprotein cholesterol <100 mg/dl and high-density lipoprotein cholesterol <50 mg/dl for men or 55 mg/dl for women while receiving stable statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target dose, 2,000 mg/day)."	5.14	The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. ( Devine, PJ; Griffen, L; Miller, M; Stanek, EJ; Taylor, AJ; Turco, M; Villines, TC; Weissman, NJ, 2010)
"To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia."	5.14	Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. ( Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP, 2010)
"Fifty patients with the metabolic syndrome (Adult Treatment Panel (ATP) III criteria) were randomised to either extended-release niacin (1000 mg/day) or placebo."	5.12	The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. ( Hammoud, R; Khan, BV; Nagamia, S; Oguchi, A; Thoenes, M; Umpierrez, GE; Vaccari, CS, 2007)
"Recent advances have provided physiological mechanisms of action of niacin on lipid metabolism and atherosclerosis."	4.89	Recent advances in niacin and lipid metabolism. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2013)
"The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis progression."	4.88	Niacin: the evidence, clinical use, and future directions. ( Gore, RS; Kim, AS; Taylor, AJ; Villines, TC, 2012)
"Niacin has been used for more than 50 years in the management of atherosclerosis and is associated with improved patient outcomes."	4.87	Effects of niacin on atherosclerosis and vascular function. ( Choudhury, RP; Digby, JE; Ruparelia, N, 2011)
"Niacin-based therapies comprehensively improve the atherogenic lipid profile, lead to atherosclerosis regression, and exert benefits across a spectrum of cardiovascular endpoints in studies based on limited patient numbers."	4.87	Optimal pharmacotherapy to combat the atherogenic lipid triad. ( Chapman, MJ; Giral, P; McGovern, ME; Redfern, JS, 2011)
"Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis."	4.87	Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. ( Hanson, J; Lukasova, M; Offermanns, S; Tunaru, S, 2011)
"The reader will gain knowledge of the development of niacin as an antiatherosclerosis treatment and of the added value that laropiprant may offer this treatment principle; and also the present place of niacin/laropiprant in the armamentarium of cardiovascular preventive drugs."	4.86	Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. ( Olsson, AG, 2010)
"Although the studies were conducted before statin therapy become standard care, and mostly in patients in secondary prevention, with various dosages of nicotinic acid 1-3g/day, this meta-analysis found positive effects of niacin alone or in combination on all cardiovascular events and on atherosclerosis evolution."	4.86	Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. ( Amarenco, P; Bruckert, E; Labreuche, J, 2010)
" In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe."	4.84	[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. ( Balcerak, M; Broncel, M; Chojnowska-Jezierska, J, 2007)
"MEDLINE was searched for articles published from 1990 through 2006 using the terms hypertriglyceridemia, dyslipidemia, and coronary heart disease, with subheadings for risk, statins, niacin, fibrates, thiazolidinediones, and omega-3 fatty acids."	4.84	Hypertriglyceridemia and cardiovascular risk reduction. ( Jacobson, TA; Miller, M; Schaefer, EJ, 2007)
" Nicotinate-curcumin (NC) is an esterification derivative of niacin and curcumin that can prevent the formation of atherosclerosis."	4.02	Nicotinate-curcumin inhibits AngII-induced vascular smooth muscle cell phenotype switching by upregulating Daxx expression. ( Cao, YM; Chen, Y; He, CP; Huo, YJ; Liao, DF; Qiu, F; Quan, WJ; Sun, SY; Tuo, QH, 2021)
"Niacin has been widely used as an antihyperlipidemic drug, but the flushing effect restricted its clinical application."	3.96	Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. ( Cai, W; Chen, J; Jiang, Y; Jin, M; Liu, P; Pi, R; Yan, J; Yao, M, 2020)
" We utilized nicotinic acid, a family member of the B-vitamin niacin (vitamin B3) that has been used in the prevention and treatment of atherosclerosis or other lipid-metabolic disorders, to treat human umbilical vein endothelial cells (HUVECs) and chick chorioallantoic membrane (CAM), and investigated its influence on angiogenesis in vitro and in vivo."	3.85	Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. ( Chen, X; Li, X; Pan, L; Yu, G, 2017)
"Our previous studies have indicated that a novel curcumin derivate nicotinate-curcumin (NC) has beneficial effects on the prevention of atherosclerosis, but the precise mechanisms are not fully understood."	3.83	Nicotinate-Curcumin Impedes Foam Cell Formation from THP-1 Cells through Restoring Autophagy Flux. ( Gu, HF; Li, HZ; Liao, DF; Tang, XQ; Tang, YL; Zheng, XL, 2016)
"BACKGROUND Niacin is a broad-spectrum lipid-regulating drug used for the clinical therapy of atherosclerosis; however, the mechanisms by which niacin ameliorates atherosclerosis are not clear."	3.81	Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. ( Guo, L; Huang, C; Liu, H; Shu, L; Su, G; Sun, G; Xu, J; Zhang, J, 2015)
"Niacin decreases atherosclerosis development mainly by reducing nonHDL-cholesterol with modest HDL-cholesterol-raising and additional anti-inflammatory effects."	3.79	Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. ( Havekes, LM; Heemskerk, MM; Jukema, JW; Kühnast, S; Louwe, MC; Pieterman, EJ; Princen, HM; Rensen, PC; Smit, JW; van den Berg, SA; van der Hoorn, JW; van Klinken, JB, 2013)
"Nicotinic acid (niacin) is a drug used to reduce the progression of atherosclerosis."	3.77	Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. ( Gille, A; Kero, J; Lukasova, M; Malaval, C; Offermanns, S, 2011)
"The termination of the Phase III clinical trial of Pfizer's CETP inhibitor torcetrapib, Investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE), due to excess mortality in the treatment group raised many questions for those involved in the discovery and development of drugs targeting high-density lipoprotein and of atherosclerosis in general."	3.74	The continuing complexities of high-density lipoprotein metabolism in drug discovery and development. ( Suckling, K, 2007)
"Combination of statins with niacin appears to be an attractive association, in the presence of mixed dyslipidemia with low HDL-c levels, when monotherapy is insufficient to achieve target lipid levels."	3.73	[Drug combinations: statins and niacin]. ( Borges, JL, 2005)
"The change in logarithmic reactive hyperemia index between 1 month and 12 months was similar in patients receiving ER-niacin vs placebo (0."	2.80	Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts ( Abdurrahim, G; Banerjee, S; Brilakis, ES; Chao, H; Christopoulos, G; Coleman, A; de Lemos, JA; Guerra, A; Han, H; Kotsia, A; McGuire, DK; Packer, M; Rangan, BV; Roesle, M; Sosa, A; Xu, H, 2015)
"Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3."	2.79	Effects of extended-release niacin with laropiprant in high-risk patients. ( Armitage, J; Aung, T; Collins, R; Craig, M; Haynes, R; Hopewell, JC; Jiang, L; Landray, MJ; Parish, S; Tomson, J; Wallendszus, K, 2014)
"This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population."	2.72	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021)
"Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries."	2.72	Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. ( Accinni, R; Bamonti, F; Bernacchi, F; Campolo, J; Caruso, R; Ciani, A; Della Noce, C; Ghersi, L; Gorini, M; Grossi, S; Ippolito, S; Lonati, S; Lorenzano, E; Novembrino, C; Rosina, M; Tonini, A, 2006)
"Hypercholesterolemia is a well-established risk factor for atherosclerotic cardiovascular disease (ASCVD)."	2.72	Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes? ( Smith, SC; Stouffer, GA; Zhou, R, 2021)
"Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)."	2.61	New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019)
"Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease."	2.53	Pleiotropic effects of niacin: Current possibilities for its clinical use. ( Hrib, J; Hromádka, R; Perlík, F; Širc, J; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2016)
"Atherosclerosis is in vivo pathology of individual cells unable to incorporate PFA and a syndrome of ω-3 and ω-6 PFA deficiency."	2.50	[The basis principles of primary prevention of atherosclerosis]. ( Titov, VN, 2014)
"Niacin also has been found to reduce inflammatory markers like C-reactive protein (CRP) and lipoprotein-associated phospholipase-A2 (Lp-PLA2) and to decrease small-dense LDL and increase large-particle LDL, all potentially anti-atherosclerotic properties."	2.49	The role of niacin in lipid-lowering treatment: are we aiming too high? ( Berthold, HK; Gouni-Berthold, I, 2013)
"In the metabolic syndrome and type 2 diabetes, excess energy intake on the background of genetic predisposition and lifestyle factors leads to the dysregulation of fatty acid metabolism and acquired insulin resistance."	2.48	Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. ( Matikainen, N; Taskinen, MR, 2012)
"Atherosclerosis is a chronic inflammatory disease affecting medium and large arteries resulting from a complex interaction between genetic and environmental risk factors that include dyslipidemia, hypertension, diabetes mellitus, and smoking."	2.47	Progress in HDL-based therapies for atherosclerosis. ( Chyu, KY; Peter, A; Shah, PK, 2011)
"Niacin is a pleiotropic drug that slows the progression of coronary artery disease and increases serum levels of the HO-1 enzymatic product bilirubin."	1.38	Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. ( Barter, PJ; Chen, K; Rye, KA; Wu, BJ, 2012)
"Flushing was the most common ADR (29% of patients during the first month of treatment)."	1.35	Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands. ( Dunkelgrun, M; Hostalek, U; Poldermans, D; Schouten, O, 2008)
"Niacin has been used for decades to lower the plasma concentrations of cholesterol, free fatty acids, and triglycerides in humans, and in addition it raises more than any other drug the levels of the protective high density lipoprotein."	1.34	Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. ( Yu, BL; Zhao, SP, 2007)

Research

Studies (152)

Authors

Clinical Trials (22)

Trial Overview

Trial Outcomes

Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI

Timeframe	Studies, this research(%)	All Research%
pre-1990	26 (17.11)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (22.37)	29.6817
2010's	85 (55.92)	24.3611
2020's	7 (4.61)	2.80

Authors	Studies
Skinner, PJ	1
Webb, PJ	1
Sage, CR	1
Dang, TH	1
Pride, CC	1
Chen, R	1
Tamura, SY	1
Richman, JG	1
Connolly, DT	1
Semple, G	1
Bai, Z	1
Zhang, J	3
Zhang, Q	1
Wang, Y	2
Li, J	1
Zhao, Q	1
Wang, Z	1
He, D	1
Liu, B	1
Kjeldsen, EW	1
Thomassen, JQ	1
Frikke-Schmidt, R	1
Wang, W	1
Wang, L	1
Zhao, Z	1
Xia, Y	1
Li, L	1
Jiang, Y	1
Jin, M	1
Chen, J	1
Yan, J	1
Liu, P	1
Yao, M	1
Cai, W	1
Pi, R	1
Lu, Y	1
Yin, J	1
Wu, X	1
Fan, Y	1
Liu, F	1
Mathew, RO	1
Rosenson, RS	3
Lyubarova, R	1
Chaudhry, R	1
Costa, SP	1
Bangalore, S	1
Sidhu, MS	1
Sun, SY	1
Cao, YM	1
Huo, YJ	1
Qiu, F	1
Quan, WJ	1
He, CP	1
Chen, Y	1
Liao, DF	2
Tuo, QH	1
Ronsein, GE	1
Vaisar, T	1
Davidson, WS	1
Bornfeldt, KE	1
Probstfield, JL	3
O'Brien, KD	1
Zhao, XQ	3
Heinecke, JW	1
Zhou, R	1
Stouffer, GA	1
Smith, SC	1
Pan, L	1
Yu, G	1
Chen, X	2
Li, X	1
Mandrika, I	1
Tilgase, A	1
Petrovska, R	1
Klovins, J	1
Roberts, WC	1
Preston Mason, R	1
Tada, H	1
Takamura, M	1
Kawashiri, MA	1
Stulnig, TM	1
Morozzi, C	1
Reindl-Schwaighofer, R	1
Stefanutti, C	1
Khoueiry, G	1
Abdallah, M	1
Saiful, F	1
Abi Rafeh, N	1
Raza, M	1
Bhat, T	1
El-Sayegh, S	1
Kalantar-Zadeh, K	1
Lafferty, J	1
Chai, JT	1
Digby, JE	3
Choudhury, RP	4
Kei, A	1
Liberopoulos, E	1
Tellis, K	1
Rizzo, M	1
Elisaf, M	1
Tselepis, A	1
Kamanna, VS	1
Ganji, SH	1
Kashyap, ML	2
Egom, EE	1
Mamas, MA	1
Soran, H	1
Gaidarov, I	1
Anthony, T	1
Maciejewski-Lenoir, D	1
Liaw, C	1
Unett, DJ	1
Kühnast, S	1
Louwe, MC	1
Heemskerk, MM	1
Pieterman, EJ	1
van Klinken, JB	1
van den Berg, SA	1
Smit, JW	1
Havekes, LM	2
Rensen, PC	2
van der Hoorn, JW	2
Princen, HM	2
Jukema, JW	2
Teo, KK	1
Goldstein, LB	1
Chaitman, BR	2
Grant, S	1
Weintraub, WS	1
Anderson, DC	1
Sila, CA	1
Cruz-Flores, S	1
Padley, RJ	2
Kostuk, WJ	1
Boden, WE	3
Manoria, PC	1
Chopra, HK	1
Parashar, SK	1
Dutta, AL	1
Pinto, B	1
Mullasari, A	1
Prajapati, S	1
Niu, N	1
Han, B	1
Sun, SZ	1
Yu, YH	1
Wang, LJ	1
Hafiane, A	1
Kellett, S	1
Genest, J	1
Kleber, ME	1
Grammer, TB	1
Kassner, U	1
Silbernagel, G	1
März, W	1
Nicholls, SJ	1
Lloyd-Jones, DM	1
Anderson, TJ	1
Desvigne-Nickens, P	1
Fleg, JL	1
McBride, R	2
Landray, MJ	2
Haynes, R	2
Hopewell, JC	1
Parish, S	1
Aung, T	1
Tomson, J	1
Wallendszus, K	1
Craig, M	1
Jiang, L	1
Collins, R	1
Armitage, J	2
Huynh, K	1
Santos-Gallego, CG	2
Rembold, CM	3
Meneses, F	1
Hu, M	1
Tomlinson, B	1
van den Oever, IA	1
Nurmohamed, MT	1
Lems, WF	1
Badimon, J	1
Mayer, L	1
Bloomfield, HE	1
deGoma, EM	1
Salavati, A	1
Shinohara, RT	1
Saboury, B	1
Pollan, L	1
Schoen, M	1
Torigian, DA	1
Mohler, ER	1
Dunbar, RL	1
Litt, HI	1
Woo, J	1
Rader, DJ	1
Alavi, A	1
Mehta, NN	1
Tietge, UJ	1
Titov, VN	1
Kotsia, AP	1
Rangan, BV	2
Christopoulos, G	2
Coleman, A	2
Roesle, M	2
Cipher, D	1
de Lemos, JA	2
McGuire, DK	2
Packer, M	2
Banerjee, S	2
Brilakis, ES	2
Guerra, A	1
Xu, H	1
Kotsia, A	1
Sosa, A	1
Chao, H	1
Han, H	1
Abdurrahim, G	1
Mateuszuk, L	1
Jasztal, A	1
Maslak, E	1
Gasior-Glogowska, M	1
Baranska, M	1
Sitek, B	1
Kostogrys, R	1
Zakrzewska, A	1
Kij, A	1
Walczak, M	1
Chlopicki, S	1
Su, G	1
Sun, G	1
Liu, H	1
Shu, L	1
Guo, L	1
Huang, C	1
Xu, J	1
Graff, EC	1
Fang, H	1
Wanders, D	1
Judd, RL	1
Gu, HF	1
Li, HZ	1
Tang, YL	1
Tang, XQ	1
Zheng, XL	1
Hannan, PA	1
Khan, JA	1
Ullah, I	1
Ullah, S	1
Zeman, M	1
Vecka, M	1
Perlík, F	1
Staňková, B	1
Hromádka, R	1
Tvrzická, E	1
Širc, J	1
Hrib, J	1
Žák, A	1
Handelsman, Y	3
Shapiro, MD	1
Daniels, SR	1
Greer, FR	1
Paragh, G	1
Harangi, M	1
László, M	1
de Haan, W	1
Berbée, JF	1
Poldermans, D	1
Dunkelgrun, M	1
Schouten, O	1
Hostalek, U	1
Watts, GF	1
Chan, DC	1
Cardenas, GA	1
Lavie, CJ	1
Cardenas, V	1
Milani, RV	1
McCullough, PA	1
Tavintharan, S	1
Lim, SC	1
Sum, CF	1
Avis, HJ	1
Vissers, MN	1
Wijburg, FA	1
Kastelein, JJ	1
Hutten, BA	1
Merkel, M	1
Vosper, H	1
McNeill, E	1
Dyar, OJ	1
Lam, V	1
Greaves, DR	1
Kłosiewicz-Latoszek, L	1
Cybulska, B	1
Bitzur, R	1
Cohen, H	1
Kamari, Y	1
Shaish, A	1
Harats, D	1
Bruckert, E	1
Labreuche, J	1
Amarenco, P	1
Parhofer, K	1
Chapman, MJ	3
Redfern, JS	2
McGovern, ME	2
Giral, P	2
Ferrario, CM	1
Villines, TC	2
Stanek, EJ	1
Devine, PJ	1
Turco, M	1
Miller, M	2
Weissman, NJ	1
Griffen, L	1
Taylor, AJ	2
Rossi, GP	1
Rizzoni, D	1
Tuohimaa, P	1
Järvilehto, M	1
Olsson, AG	1
Judge, EP	1
Phelan, D	1
O'Shea, D	1
Lee, JM	1
Rubenfire, M	1
Brook, RD	1
Montecucco, F	1
Quercioli, A	1
Dallegri, F	1
Viviani, GL	1
Mach, F	1
Ruparelia, N	1
Insull, W	1
Toth, PP	1
Superko, HR	1
Thakkar, RB	1
Krause, S	1
Jiang, P	1
Parreno, RA	1
Dobiásová, M	1
Frohlich, J	1
Sedová, M	1
Cheung, MC	1
Brown, BG	1
Lukasova, M	2
Malaval, C	1
Gille, A	2
Kero, J	1
Offermanns, S	3
Wierzbicki, AS	1
Safarova, MS	1
Trukhacheva, EP	1
Ezhov, MV	1
Afanas'eva, OI	1
Afanas'eva, MI	1
Tripoten', MI	1
Liakishev, AA	1
Pokrovskiĭ, SN	1
Chyu, KY	1
Peter, A	1
Shah, PK	1
Ingersoll, MA	1
Potteaux, S	1
Alvarez, D	1
Hutchison, SB	1
van Rooijen, N	1
Randolph, GJ	1
Hanson, J	1
Tunaru, S	1
Zambon, A	1
Kim, AS	1
Gore, RS	1
Giugliano, RP	1
Anderson, T	1
Desvignes-Nickens, P	1
Koprowicz, K	1
Teo, K	1
Weintraub, W	1
Wu, BJ	1
Chen, K	1
Barter, PJ	1
Rye, KA	1
Bloomgarden, Z	2
Shil, AB	1
Schaefer, JR	1
Bays, H	1
Giezek, H	1
McKenney, JM	1
O'Neill, EA	1
Tershakovec, AM	1
Brouwers, MC	1
Stehouwer, CD	1
Kaski, JC	1
Vítek, L	1
Vaníková, J	1
Nachtigal, P	1
Chennamsetty, I	1
Kostner, KM	1
Claudel, T	1
Vinod, M	1
Frank, S	1
Weiss, TS	1
Trauner, M	1
Kostner, GM	1
Matikainen, N	1
Taskinen, MR	1
Gouni-Berthold, I	1
Berthold, HK	1
FRIEDMAN, M	1
BYERS, SO	1
DE LA RIEGA, E	1
BURRIER, C	1
PALLUCCHINI, M	1
LJUNGGREN, H	1
GRISSLER, J	1
PROBST, F	1
MOSSO, HE	1
CAVA, EE	1
ACHOR, RW	1
BERGE, KG	1
WAKIM, KG	1
EDWARDS, JE	1
McKENZIE, BF	1
BARKER, NW	1
COCUZZA, F	1
PRIVITERA, M	1
MISTRETTA, A	1
CELESTI, G	1
DAVIS, OF	1
BECK, C	1
BERGAL, M	1
SLOAN, N	1
LEVINE, AJ	1
FLORIAN, HJ	1
ILIESCU, CC	1
ILIESCU, M	1
ROMAN, L	1
IACOBINI, P	1
CONSTANTINESCU, S	1
NUTU, S	1
BARNETT, AJ	1
CARSON, VJ	1
BURSTEIN, J	1
TELKKA, A	1
KIMMERLING, HW	1
SCHULZE, G	1
POLIVODA, H	1
KOESTERING, H	1
VASKO, J	1
YOUNGER, R	1
STEPHENSON, SE	1
MAZZEI, ES	1
MAZZEI, CM	1
IBRAHIM, MB	1
DOVGIALLO, GK	1
GULKO, IS	1
LUKOMSKII, PE	1
SZEGEDI, G	1
LEOEVEY, A	1
PETRANYI, G	1
KLEIN, L	2
SCHOEN, H	1
STUETTGEN, G	1
LEUTIGER, H	1
VASTESAEGER, MM	1
LIPTON, P	1
MICHELS, JG	1
Sampietro, T	1
Bigazzi, F	1
Dal Pino, B	1
Puntoni, M	1
Bionda, A	1
Parhofer, KG	1
Westphal, S	1
Borucki, K	1
Luley, C	1
Martens-Lobenhoffer, J	1
Bode-Böger, SM	1
Borges, JL	1
Accinni, R	1
Rosina, M	1
Bamonti, F	1
Della Noce, C	1
Tonini, A	1
Bernacchi, F	1
Campolo, J	1
Caruso, R	1
Novembrino, C	1
Ghersi, L	1
Lonati, S	1
Grossi, S	1
Ippolito, S	1
Lorenzano, E	1
Ciani, A	1
Gorini, M	1
Hersberger, M	1
von Eckardstein, A	1
Carlson, LA	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273]	Phase 4	217 participants (Actual)	Interventional	2001-05-01	Completed
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH[NCT00880178]		324 participants (Actual)	Observational	2008-05-31	Completed
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events[NCT00120289]	Phase 3	3,414 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to AIM-HIGH was stopped on the recommendation of the DSMB because of lack of efficacy of niacin in preventing primary outcome events.)
Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526]	Phase 4	450 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Influence of Pelacarsen on Arterial Wall Properties and Risk Factors in Patients After Myocardial Infarction With High Lp(a) Values[NCT04993664]		0 participants (Actual)	Interventional	2021-10-01	Withdrawn (stopped due to Administrative reason)
Genetic, Biochemical and Functional Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment Options[NCT04613167]		70 participants (Anticipated)	Interventional	2020-11-10	Recruiting
Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia[NCT01010516]	Phase 4	120 participants (Anticipated)	Interventional	2009-10-31	Recruiting
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant[NCT00461630]	Phase 3	25,673 participants (Actual)	Interventional	2007-01-31	Completed
Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial[NCT03542110]	Phase 4	46 participants (Actual)	Interventional	2018-08-04	Terminated (stopped due to Withdrawal of medication and funding support by Sponsor)
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial[NCT01221402]	Phase 2	38 participants (Actual)	Interventional	2010-10-31	Completed
Obesity in Pediatric Sickle Cell Disease: A New Phenomenon[NCT04676113]		100 participants (Actual)	Observational	2021-03-01	Completed
Establishment of the Pediatric Obesity Weight Evaluation Registry (POWER): A Prospective Pilot Project of Children and Adolescents Presenting for Weight Management[NCT02121132]		10,000 participants (Anticipated)	Observational [Patient Registry]	2014-05-31	Recruiting
The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients[NCT03973203]		15 participants (Actual)	Interventional	2014-06-01	Completed
NiaMIT (NiaMIT_0001) Continuation for Early-stage Mitochondrial Myopathy Patients to Investigate the Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance[NCT04538521]		3 participants (Actual)	Interventional	2019-02-11	Completed
Post-prandial Effects of Extra Virgin Olive Oil on Endothelial Function in Adults at Risk for Type 2 Diabetes: A Randomized Crossover Controlled Trial[NCT04025281]		20 participants (Actual)	Interventional	2019-07-09	Completed
The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429]		35 participants (Actual)	Interventional	2020-06-09	Completed
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657]	Phase 4	400 participants (Anticipated)	Interventional	2006-11-30	Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population[NCT02515747]		1,400 participants (Actual)	Interventional	1993-01-31	Completed
Relationships Between Lipoprotein(a) Levels and Aortic Valve Calcification in Patients With Heterozygous Familial Hypercholesterolemia[NCT02976818]		173 participants (Actual)	Observational	2017-04-30	Completed
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease[NCT02992548]	Phase 4	62 participants (Actual)	Interventional	2015-09-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes[NCT00485758]	Phase 3	796 participants (Actual)	Interventional	2007-07-31	Completed
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART[NCT01683656]	Phase 4	4 participants (Actual)	Interventional	2012-08-31	Terminated (stopped due to Withdrawal of IMP from the market. Data on risk-benefit ratio pending.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI

Intervention	mm^3/year (Mean)
1 - Single Therapy Group	-4.6
2 - Double Therapy Group	-15.1
3 - Triple Therapy Group	-9.4

Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions

Intervention	percentage change/year (Mean)
	LRNC change	Wall Volume change
1 - Single Therapy Group	-1.6	-0.6
2 - Double Therapy Group	-3.6	-1.4
3 - Triple Therapy Group	-2.8	-1.2

Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5

Cardiovascular Mortality

Intervention	Participants (Count of Participants)
	Composite Measured at Year 3	Composite Measured at Year 4 (cumulative)	Composite Measured at Year 5 (cumulative)
1 - Single Therapy Group	6	7	9
2 - Double Therapy Group	6	11	11
3 - Triple Therapy Group	7	9	9

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination), for an average of 36 months follow-up, maximum 66 months.

Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary Syndrome (ACS), or Symptom-driven Coronary or Cerebral Revascularization

Intervention	participants (Number)
ERN + Simvastatin	45
Placebo + Simvastatin	38

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months.

Composite Endpoint of CHD Death, Non-fatal MI, High-risk ACS or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	282
Placebo + Simvastatin	274

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Composite Endpoint of CHD Death, Non-fatal MI, or Ischemic Stroke

Intervention	participants (Number)
ERN + Simvastatin	171
Placebo + Simvastatin	158

(NCT00120289)
Timeframe: Time to first event measured from date of randomization through last follow-up visit (common termination) for an average of 36 months follow-up, maximum 66 months

Coronary or Non-coronary Revascularisation

Intervention	participants (Number)
ERN + Simvastatin	156
Placebo + Simvastatin	138

(NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Coronary Events

Intervention	participants (Number)
ER Niacin/Laropiprant	807
Placebo	897

Non-fatal myocardial infarction (MI) or coronary death (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Major Vascular Event

Intervention	participants (Number)
ER Niacin/Laropiprant	668
Placebo	694

Non-fatal myocardial infarction or coronary death, non-fatal or fatal stroke, or revascularisation (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Mortality

Intervention	participants (Number)
ER Niacin/Laropiprant	1696
Placebo	1758

All-cause mortality (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Stroke

Intervention	participants (Number)
ER Niacin/Laropiprant	798
Placebo	732

Fatal or non-fatal (NCT00461630)
Timeframe: During scheduled treatment period (median duration 3.9 years)

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	participants (Number)
ER Niacin/Laropiprant	498
Placebo	499

After 12 weeks of treatment, to assess the increase of high-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	Percent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant	25.4
Placebo	2.2

After 12 Weeks of treatment, to assess the reduction of low-density lipoprotein cholesterol in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Triglycerides in Patients With Type 2 Diabetes When Compared to Placebo

Intervention	Percent change at Wk 12 compared to Bl (Least Squares Mean)
Extended Release Niacin/Laropiprant	-15.8
Placebo	2.1

after 12 weeks of treatment, to assess the reduction of triglycerides in patients with Type 2 diabetes when compared to placebo (NCT00485758)
Timeframe: Baseline and 12 Weeks

Article	Year
HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. Biochimica et biophysica acta. Molecular and cell biology of lipids, 2022, Volume: 1867, Issue:1 Topics: Adaptor Protein Complex 3; Adaptor Protein Complex beta Subunits; Atherosclerosis; Cholesterol Ester	2022
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3 Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-	2021
Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes? Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:6 Topics: Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hy	2021
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. Current atherosclerosis reports, 2019, 01-12, Volume: 21, Issue:1 Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa	2019
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of atherosclerosis and thrombosis, 2019, Jul-01, Volume: 26, Issue:7 Topics: Apolipoproteins B; Atherosclerosis; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2019
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of atherosclerosis and thrombosis, 2019, Jul-01, Volume: 26, Issue:7 Topics: Apolipoproteins B; Atherosclerosis; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2019
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of atherosclerosis and thrombosis, 2019, Jul-01, Volume: 26, Issue:7 Topics: Apolipoproteins B; Atherosclerosis; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2019
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. Journal of atherosclerosis and thrombosis, 2019, Jul-01, Volume: 26, Issue:7 Topics: Apolipoproteins B; Atherosclerosis; Biomarkers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibito	2019
Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Current atherosclerosis reports, 2019, 07-27, Volume: 21, Issue:10 Topics: Adult; Antibodies, Monoclonal, Humanized; Atherosclerosis; Blood Component Removal; Cholesterol, LDL	2019
High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. International urology and nephrology, 2014, Volume: 46, Issue:1 Topics: Acetamides; Acetates; Acetyl-CoA C-Acetyltransferase; Anti-Inflammatory Agents; Anticholesteremic Ag	2014
GPR109A and vascular inflammation. Current atherosclerosis reports, 2013, Volume: 15, Issue:5 Topics: Arrestins; Atherosclerosis; Humans; Hypolipidemic Agents; Lipoproteins; Niacin; Receptors, G-Protein	2013
Recent advances in niacin and lipid metabolism. Current opinion in lipidology, 2013, Volume: 24, Issue:3 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL;	2013
HDL quality or cholesterol cargo: what really matters--spotlight on sphingosine-1-phosphate-rich HDL. Current opinion in lipidology, 2013, Volume: 24, Issue:4 Topics: Animals; Atherosclerosis; Cardiotonic Agents; Cholesterol, HDL; Coronary Artery Disease; Drug Therap	2013
The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian heart journal, 2013, Volume: 65, Issue:6 Topics: Atherosclerosis; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Management;	2013
Treatment options for low high-density lipoproteins. Current opinion in endocrinology, diabetes, and obesity, 2014, Volume: 21, Issue:2 Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti	2014
Role of HDL in those with diabetes. Current cardiology reports, 2014, Volume: 16, Issue:9 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitu	2014
[The basis principles of primary prevention of atherosclerosis]. Klinicheskaia meditsina, 2014, Volume: 92, Issue:12 Topics: Atherosclerosis; Humans; Hypolipidemic Agents; Niacin; Primary Prevention	2014
Anti-inflammatory effects of the hydroxycarboxylic acid receptor 2. Metabolism: clinical and experimental, 2016, Volume: 65, Issue:2 Topics: Animals; Atherosclerosis; Colitis; Diabetic Retinopathy; Humans; Inflammation; Mice; Neoplasms; Neur	2016
Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta pharmaceutica (Zagreb, Croatia), 2016, Dec-01, Volume: 66, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Disease Progression	2016
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:1 Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; H	2017
Lipid screening and cardiovascular health in childhood. Pediatrics, 2008, Volume: 122, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Child; Di	2008
Lipid screening and cardiovascular health in childhood. Pediatrics, 2008, Volume: 122, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Child; Di	2008
Lipid screening and cardiovascular health in childhood. Pediatrics, 2008, Volume: 122, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Child; Di	2008
Lipid screening and cardiovascular health in childhood. Pediatrics, 2008, Volume: 122, Issue:1 Topics: Anion Exchange Resins; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Child; Di	2008
[New trends in lipidology: the increasing role of HDL-cholesterol]. Orvosi hetilap, 2008, Jul-27, Volume: 149, Issue:30 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Pr	2008
The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Reviews in cardiovascular medicine, 2008,Fall, Volume: 9, Issue:4 Topics: Apolipoprotein A-I; Atherosclerosis; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; C	2008
The use of lipid-lowering drug therapy in children and adolescents. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:3 Topics: Adolescent; Atherosclerosis; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Child; Chole	2009
[Diabetic dyslipoproteinemia: beyond LDL]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chy	2009
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. British journal of pharmacology, 2009, Volume: 158, Issue:2 Topics: Animals; Atherosclerosis; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Medication Adher	2009
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. British journal of pharmacology, 2009, Volume: 158, Issue:2 Topics: Animals; Atherosclerosis; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Medication Adher	2009
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. British journal of pharmacology, 2009, Volume: 158, Issue:2 Topics: Animals; Atherosclerosis; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Medication Adher	2009
Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia. British journal of pharmacology, 2009, Volume: 158, Issue:2 Topics: Animals; Atherosclerosis; Drug Design; Dyslipidemias; Humans; Hypolipidemic Agents; Medication Adher	2009
[Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia]. Kardiologia polska, 2005, Volume: 62 Suppl 2 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Clofibric Acid; Drug Therapy, Combination; Dyslipi	2005
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Complications	2009
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis, 2010, Volume: 210, Issue:2 Topics: Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Cholesterol, HDL; Humans; Hydroxymethylg	2010
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology & therapeutics, 2010, Volume: 126, Issue:3 Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combinati	2010
Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combinat	2010
Beyond statin therapy: a review of the management of residual risk in diabetes mellitus. Journal of the Royal Society of Medicine, 2010, Volume: 103, Issue:9 Topics: Atherosclerosis; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combinatio	2010
Atherosclerosis regression and high-density lipoproteins. Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:9 Topics: Animals; Atherosclerosis; Cholesterol Ester Transfer Proteins; Disease Progression; Humans; Hypolipi	2010
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. The American journal of medicine, 2010, Volume: 123, Issue:10 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combinatio	2010
New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:10 Topics: Animals; Atherosclerosis; Clinical Trials as Topic; Humans; Hypolipidemic Agents; Niacin; Receptors,	2010
Effects of niacin on atherosclerosis and vascular function. Current opinion in cardiology, 2011, Volume: 26, Issue:1 Topics: Atherosclerosis; Endothelium, Vascular; Humans; Hypolipidemic Agents; Inflammation; Lipid Metabolism	2011
Optimal pharmacotherapy to combat the atherogenic lipid triad. Current opinion in cardiology, 2011, Volume: 26, Issue:5 Topics: Atherosclerosis; Dyslipidemias; Fibric Acids; Humans; Hypolipidemic Agents; Niacin; Treatment Outcom	2011
Progress in HDL-based therapies for atherosclerosis. Current atherosclerosis reports, 2011, Volume: 13, Issue:5 Topics: Animals; Apolipoproteins; Atherosclerosis; Dyslipidemias; Endothelium, Vascular; Fibric Acids; Fibri	2011
Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends in pharmacological sciences, 2011, Volume: 32, Issue:12 Topics: Animals; Atherosclerosis; Flushing; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Langerha	2011
Niacin: the evidence, clinical use, and future directions. Current atherosclerosis reports, 2012, Volume: 14, Issue:1 Topics: Atherosclerosis; Disease Progression; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Niacin	2012
[HDL level or HDL function as the primary target in preventive cardiology]. Herz, 2012, Volume: 37, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Choles	2012
Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Current cardiology reports, 2012, Volume: 14, Issue:6 Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fibric Acids;	2012
The role of niacin in lipid-lowering treatment: are we aiming too high? Current pharmaceutical design, 2013, Volume: 19, Issue:17 Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination	2013
DIETETIC AND PHARMACOLOGIC APPROACH TO ATHEROSCLEROSIS. The Journal of the Egyptian Medical Association, 1963, Volume: 46 Topics: Aminosalicylic Acid; Aminosalicylic Acids; Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Die	1963
HDL: the 'new' target of cardiovascular medicine. International journal of cardiology, 2006, Apr-04, Volume: 108, Issue:2 Topics: Animals; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Homeostasis; Humans; Hypolipoproteinemia	2006
The potential role of HDL- and LDL-cholesterol modulation in atheromatous plaque development. Current medical research and opinion, 2005, Volume: 21 Suppl 6 Topics: Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-Co	2005
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2005, Volume: 113, Issue:8 Topics: Arteries; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Drug Evaluation; Humans; Hyperlipidem	2005
Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. Handbook of experimental pharmacology, 2005, Issue:170 Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bio	2005
Nicotinic acid and other therapies for raising high-density lipoprotein. Current opinion in cardiology, 2006, Volume: 21, Issue:4 Topics: Atherosclerosis; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;	2006
To statin or to non-statin in coronary disease--considering absolute risk is the answer. Atherosclerosis, 2007, Volume: 195, Issue:1 Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet;	2007
HDL elevators and mimetics--emerging therapies for atherosclerosis. Cardiovascular & hematological agents in medicinal chemistry, 2007, Volume: 5, Issue:1 Topics: Animals; Apolipoprotein A-I; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Casset	2007
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:127 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric	2007
Hypertriglyceridemia and cardiovascular risk reduction. Clinical therapeutics, 2007, Volume: 29, Issue:5 Topics: Atherosclerosis; Cardiovascular Diseases; Clofibric Acid; Coronary Disease; Fatty Acids, Omega-3; Hu	2007
Nicotinic acid: pharmacological effects and mechanisms of action. Annual review of pharmacology and toxicology, 2008, Volume: 48 Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperlipidemias	2008

Article	Year
5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Animals; Atherosclerosis; Carboxylic Acids; Chemistry, Pharmaceutical; CHO Cells; Cricetinae; Cricet	2009
Anti-atherosclerosis effect of H Bioorganic & medicinal chemistry, 2019, 08-01, Volume: 27, Issue:15 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Cell Line; Cell Pro	2019
Two Mn(II) and Zn(II) Coordination Polymers: Aqueous-Phase Detection of Nitroaromatic Explosives and Protective Effect on Atherosclerosis. Journal of fluorescence, 2022, Volume: 32, Issue:2 Topics: Animals; Atherosclerosis; Coordination Complexes; Cytokines; Endothelial Cells; Enzyme-Linked Immuno	2022
Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects. European journal of pharmacology, 2020, Feb-05, Volume: 868 Topics: Animals; Atherosclerosis; Cell Line; Cricetulus; Dimerization; Disease Models, Animal; Drug Design;	2020
Nicotinate-curcumin inhibits AngII-induced vascular smooth muscle cell phenotype switching by upregulating Daxx expression. Cell adhesion & migration, 2021, Volume: 15, Issue:1 Topics: Atherosclerosis; Cell Movement; Cell Proliferation; Cells, Cultured; Co-Repressor Proteins; Curcumin	2021
Nicotinic acid inhibits angiogenesis likely through cytoskeleton remodeling. Organogenesis, 2017, 10-02, Volume: 13, Issue:4 Topics: Actins; Angiogenesis Inducing Agents; Animals; Atherosclerosis; Blood Vessels; Cell Movement; Cell P	2017
Hydroxycarboxylic Acid Receptor Ligands Modulate Proinflammatory Cytokine Expression in Human Macrophages and Adipocytes without Affecting Adipose Differentiation. Biological & pharmaceutical bulletin, 2018, Volume: 41, Issue:10 Topics: Adipocytes; Adipogenesis; Adipose Tissue; Atherosclerosis; Cells, Cultured; Cytokines; Gene Expressi	2018
From the Editor Pellagra, Osler, Roberts, Goldberger, the Atherosclerotic Diet, Niacin, the Beginning of the Atherosclerotic Epidemic, and the First Lipid-Altering Drug. The American journal of cardiology, 2019, 02-15, Volume: 123, Issue:4 Topics: Atherosclerosis; Epidemics; History, 19th Century; History, 20th Century; Humans; Hypolipidemic Agen	2019
Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential. Cellular signalling, 2013, Volume: 25, Issue:10 Topics: Adipocytes; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, S	2013
Niacin Reduces Atherosclerosis Development in APOE3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol. PloS one, 2013, Volume: 8, Issue:6* Topics: Animals; Apolipoprotein E3; Atherosclerosis; Biological Transport; Cholesterol; Cholesterol Ester Tr	2013
[Effects of niacin on cell adhesion and early atherogenesis: involvement of the p38 mitogen-activated protein kinases pathway]. Zhonghua er ke za zhi = Chinese journal of pediatrics, 2013, Volume: 51, Issue:11 Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Enzyme Inhibitors; Gene Expression Regulation; Huma	2013
Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis. Drugs, 2014, Volume: 74, Issue:5 Topics: Animals; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Myocardial	2014
Niacin's effect on cardiovascular risk: have we finally learned our lesson? Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:5 Topics: Arterial Occlusive Diseases; Atherosclerosis; Chemical and Drug Induced Liver Injury; Cholesterol, H	2014
Niacin and HDL cholesterol--time to face facts. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Safety profile of extended-release niacin in the AIM-HIGH trial. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Atherosclerosis; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hydroxymethylglutar	2014
Dyslipidaemia: Niacin-laropiprant fails to reduce the risk of vascular events. Nature reviews. Cardiology, 2014, Volume: 11, Issue:10 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
Niacin for reduction of cardiovascular risk. The New England journal of medicine, 2014, 11-13, Volume: 371, Issue:20 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
ACP Journal Club: adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events. Annals of internal medicine, 2014, Nov-18, Volume: 161, Issue:10 Topics: Atherosclerosis; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Infections; Ma	2014
HDL - Hope Dies Last? Current opinion in lipidology, 2015, Volume: 26, Issue:2 Topics: Atherosclerosis; Cholesterol, HDL; Humans; Hypolipidemic Agents; Niacin	2015
Antiatherosclerotic Effects of 1-Methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient Mice: A Comparison with Nicotinic Acid. The Journal of pharmacology and experimental therapeutics, 2016, Volume: 356, Issue:2 Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Female; Mice; Mice, Inbred C57BL; Mice, Knockout	2016
Niacin Suppresses Progression of Atherosclerosis by Inhibiting Vascular Inflammation and Apoptosis of Vascular Smooth Muscle Cells. Medical science monitor : international medical journal of experimental and clinical research, 2015, Dec-29, Volume: 21 Topics: Animals; Apolipoproteins E; Apoptosis; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Cy	2015
Nicotinate-Curcumin Impedes Foam Cell Formation from THP-1 Cells through Restoring Autophagy Flux. PloS one, 2016, Volume: 11, Issue:4 Topics: Adenine; Atherosclerosis; Autophagy; Cell Line; Chloroquine; Cholesterol; Curcumin; Foam Cells; Huma	2016
Synergistic combinatorial antihyperlipidemic study of selected natural antioxidants; modulatory effects on lipid profile and endogenous antioxidants. Lipids in health and disease, 2016, Sep-09, Volume: 15 Topics: Animals; Antioxidants; Atherosclerosis; Biological Products; Drug Synergism; Humans; Hypolipidemic A	2016
To statin or to non-statin in coronary disease-considering absolute risk is the answer. Atherosclerosis, 2008, Volume: 200, Issue:2 Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Aci	2008
Bibliography. Current world literature. HDL cholesterol. Current opinion in cardiology, 2008, Volume: 23, Issue:4 Topics: Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Humans; Hypo	2008
Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE3Leiden.CETP mice. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:11* Topics: Animals; Apolipoprotein A-I; Apolipoprotein E3; Atherosclerosis; Bile; Cholesterol Ester Transfer Pr	2008
Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands. European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2008, Volume: 41, Issue:4 Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Delayed-Action Preparations	2008
Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:11 Topics: Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Cholesterol Ester Transfer Proteins	2008
Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic & clinical pharmacology & toxicology, 2009, Volume: 104, Issue:3 Topics: Atherosclerosis; Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells	2009
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis, 2010, Volume: 209, Issue:1 Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosi	2010
[Statin plus niacin or ezetimibe? What combination for which patients?]. MMW Fortschritte der Medizin, 2009, Dec-03, Volume: 151, Issue:49-50 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Coronary Disease; Dr	2009
ARBITER 6-HALTS. Does it have the power to settle all matters? Therapeutic advances in cardiovascular disease, 2010, Volume: 4, Issue:2 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Azetidines; Drug Therapy, Combination; Ezetimibe;	2010
Therapy: raising HDL cholesterol levels: a flight of Icarus? Nature reviews. Endocrinology, 2010, Volume: 6, Issue:5 Topics: Atherosclerosis; Azetidines; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials a	2010
Niacin in the prevention of atherosclerosis: Significance of vasodilatation. Medical hypotheses, 2010, Volume: 75, Issue:4 Topics: Atherosclerosis; Cell Hypoxia; Humans; Models, Biological; Niacin; Vasa Vasorum; Vasodilation	2010
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. The Journal of clinical investigation, 2011, Volume: 121, Issue:3 Topics: Adipocytes; Animals; Aorta; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 1	2011
Niacin: the only vitamin that reduces cardiovascular events. International journal of clinical practice, 2011, Volume: 65, Issue:4 Topics: Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Flushing; Forecasting; Human	2011
Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis. Immunobiology, 2012, Volume: 217, Issue:5 Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Movement; Dendritic Cells; Dermatitis, Contact; Fe	2012
Residual cardiovascular risk in secondary prevention. Internal and emergency medicine, 2011, Volume: 6 Suppl 1 Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Female; Fibric Acids; Humans; Hydroxymet	2011
Niacin at 56 years of age--time for an early retirement? The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Atherosclerosis; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H	2011
Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation, 2012, Jan-03, Volume: 125, Issue:1 Topics: Animals; Atherosclerosis; Cells, Cultured; Coronary Vessels; Enzyme Induction; Heme Oxygenase-1; Hum	2012
Did AIM-HIGH aim too low? Journal of diabetes, 2012, Volume: 4, Issue:1 Topics: Atherosclerosis; Cholesterol, HDL; Clinical Trials as Topic; Global Health; Humans; Metabolic Syndro	2012
Termination of Atherothrombosis Intervention in Metabolic Syndrome with Low High-Density Lipoprotein Cholesterol and High Triglycerides: Impact on Global Health Study and decision to use extended-release niacin in elderly. Journal of the American Geriatrics Society, 2011, Volume: 59, Issue:12 Topics: Aged; Atherosclerosis; Cholesterol, HDL; Delayed-Action Preparations; Early Termination of Clinical	2011
An interview with the authors of Did AIM-HIGH aim too low. Interview by Jinghong Xu. Journal of diabetes, 2012, Volume: 4, Issue:1 Topics: Atherosclerosis; Cholesterol, HDL; Clinical Trials as Topic; Humans; Metabolic Syndrome; Niacin; Tri	2012
Niacin in cardiovascular patients receiving statins. The New England journal of medicine, 2012, 03-29, Volume: 366, Issue:13 Topics: Atherosclerosis; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H	2012
HDL- cholesterol: a nut too hard to crack? Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:5 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Ch	2012
Letter by Vitek et al regarding article, "niacin inhibits vascular inflammation via the induction of heme oxygenase-1". Circulation, 2012, Aug-14, Volume: 126, Issue:7 Topics: Animals; Atherosclerosis; Coronary Vessels; Heme Oxygenase-1; Humans; Inflammation Mediators; Male;	2012
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. Journal of lipid research, 2012, Volume: 53, Issue:11 Topics: Animals; Apolipoproteins A; Atherosclerosis; Cells, Cultured; Cyclic AMP; Gene Expression; Hep G2 Ce	2012
Evaluation of nicotinic acid as an hypocholesteremic and anti-atherogenic substance. The Journal of clinical investigation, 1959, Volume: 38, Issue:8 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Hematologic Diseases; Humans; Niacin; Nicotinic Acid	1959
[Studies of blood lipids in relation to atherosclerosis. The effect of nicotinic acid on the electrophoretic lipidogram in atherosclerosis]. El Dia medico, 1960, Sep-26, Volume: 32 Topics: Arteriosclerosis; Atherosclerosis; Humans; Lipids; Niacin; Nicotinic Acids	1960
[Effect of nicotinic acid on experimental atheromatosis]. Archivio di patologia e clinica medica, 1960, Volume: 37 Topics: Arteriosclerosis; Atherosclerosis; Niacin; Nicotinic Acids	1960
[Nicotinic acid treatment in hypercholesterolemia and atheromatosis]. Svenska lakartidningen, 1961, Mar-10, Volume: 58 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Hypercholesterolemia; Niacin; Nicotinic Acids	1961
[Action of nicotinic acid on cholesterol and lipoproteins in atherosclerosis]. La Semana medica, 1960, Jul-07, Volume: 117 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Lipoproteins; Niacin; Nicotinic Acids	1960
Effect of nicotinic acid on experimental atheromatosis of rabbits. Proceedings of the staff meetings. Mayo Clinic, 1959, Oct-14, Volume: 34 Topics: Animals; Atherosclerosis; Lagomorpha; Niacin; Nicotinic Acids; Rabbits	1959
[Research on the therapeutic possibilities of nicotinic acid in massive doses in atherosclerosis]. Atti della Societa italiana di cardiologia, 1959, Volume: 21(2) Topics: Atherosclerosis; Humans; Niacin; Nicotinic Acids; Research	1959
Some observations on the relationships between atherosclerosis, hyperlipemia, and D-thyroxine. American heart journal, 1962, Volume: 64 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Dextrothyroxine; Estrogens; Humans; Hyperlipidemias;	1962
[The prophylaxis of atherosclerosis in occupational stress]. Munchener medizinische Wochenschrift (1950), 1962, Apr-27, Volume: 104 Topics: Arteriosclerosis; Atherosclerosis; Biomedical Research; Humans; Inositol; Lipids; Niacin; Nicotinic	1962
[The effect of nicotinic acid on blood lipids in atherosclerosis]. Medicina interna, 1963, Volume: 15 Topics: Arteriosclerosis; Atherosclerosis; Humans; Lipids; Niacin; Nicotinic Acids	1963
Reduction of plasma cholesterol levels in atherosclerosis by diet and drug treatment. Australasian annals of medicine, 1963, Volume: 12 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Diet Therapy; Fats; Humans; Hypercholesterolem	1963
Effect of nicotinic acid and magnesium nicotinate on cholesterol-induced atherosclerosis in cockerels. Acta pathologica et microbiologica Scandinavica, 1962, Volume: 56 Topics: Animals; Arteriosclerosis; Atherosclerosis; Chickens; Cholesterol; Humans; Magnesium; Male; Niacin;	1962
Concepts, theory and treatment of atherosclerosis. Journal of the American Geriatrics Society, 1962, Volume: 10 Topics: Alcohols; Arteriosclerosis; Atherosclerosis; Fats, Unsaturated; Heparin; Hypercholesterolemia; Niaci	1962
[INDIRECT FIBRINOLYSIS AS A THERAPEUTIC PRINCIPLE IN THE TREATMENT OF ATHEROSCLEROSIS]. Munchener medizinische Wochenschrift (1950), 1963, Aug-30, Volume: 105 Topics: Arteriosclerosis; Atherosclerosis; Fibrinolysis; Inositol; Niacin; Nicotinic Acids; Phospholipids; S	1963
ANTI-ATHEROGENIC EFFECTS OF ALUMINUM NICOTINATE IN THE HYPERCHOLESTEROLEMIC CANINE. Surgical forum, 1963, Volume: 14 Topics: Aluminum; Aluminum Compounds; Animals; Arteriosclerosis; Atherosclerosis; Dogs; Hypercholesterolemia	1963
[ATHEROSCLEROSIS. RECENT ASPECTS OF ITS BIOCHEMISTRY, PATHOGENESIS AND CLINICAL FEATURES AND OF THE ACTION OF SOME HYPOCHOLESTEREMIC DRUGS]. El Dia medico, 1963, Volume: 35 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Diet; Diet Therapy; Fatty Acids; Lipid Metabolism; L	1963
[USE OF NICOTINIC ACID IN ATHEROSCLEROSIS]. Terapevticheskii arkhiv, 1963, Volume: 35 Topics: Arteriosclerosis; Atherosclerosis; Blood Protein Electrophoresis; Cholesterol; Lecithins; Niacin; Ni	1963
[PROBLEMS IN DRUG THERAPY AND ATHEROSCLEROSIS PREVENTION]. Terapevticheskii arkhiv, 1963, Volume: 35 Topics: Arteriosclerosis; Atherosclerosis; Choline; Fatty Acids; Folic Acid; Hematinics; Humans; Lipid Metab	1963
[PROLONGED TREATMENT OF ATHEROSCLEROSIS OBLITERANS WITH LARGE DOSES OF NICOTINIC ACID]. Orvosi hetilap, 1963, Dec-29, Volume: 104 Topics: Arteriosclerosis Obliterans; Atherosclerosis; Cholesterol; Niacin; Nicotinic Acids	1963
[SODIUM CITRATE IN ATHEROSCLEROSIS]. La Semana medica, 1963, Dec-16, Volume: 123 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Citrates; Injections, Intramuscular; Injections, Int	1963
[THE SIGNIFICANCE OF INSUFFICIENT CLEARANCE IN ATHEROGENESIS]. Munchener medizinische Wochenschrift (1950), 1963, Dec-13, Volume: 105 Topics: Arteriosclerosis; Atherosclerosis; Dietary Fats; Glycerides; Heparin; Heparinoids; Hypercholesterole	1963
[ATHEROSCLEROSIS AND CHOLESTEROLEMIA]. La Semana medica, 1963, Dec-09, Volume: 123 Topics: Arteriosclerosis; Atherosclerosis; Enzyme Inhibitors; Estrogens; Fats, Unsaturated; Heparin; Hyperch	1963
[ON CHOLESTEROL MOBILIZATION IN THE TREATMENT OF XANTHOMA AND ATHEROSCLEROSIS]. Arzneimittel-Forschung, 1963, Volume: 13 Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Drug Therapy; Heparin; Humans; Hypercholesterolemia;	1963
[BLOOD LIPIDS IN ATHEROSCLEROSIS AND THE ACTION OF SOME AGENTS MODIFYING LIPEMIA]. Acta gastro-enterologica Belgica, 1964, Volume: 27 Topics: Androsterone; Anticholesteremic Agents; Arteriosclerosis; Atherosclerosis; Butyrates; Cholesterol; D	1964
THE EFFECTS OF NICOTINIC ACID ON RABBIT HYPERCHOLESTEROLEMIA AND ATHEROGENESIS. Geriatrics, 1965, Volume: 71 Topics: Aorta; Arteriosclerosis; Atherosclerosis; Blood Chemical Analysis; Cholesterol; Diet; Hypercholester	1965
Treatment with niacin lowers ADMA. Atherosclerosis, 2006, Volume: 184, Issue:2 Topics: Adult; Aged; Arginine; Atherosclerosis; Biomarkers; Female; Humans; Hypolipidemic Agents; Male; Midd	2006
[Drug combinations: statins and niacin]. Arquivos brasileiros de cardiologia, 2005, Volume: 85 Suppl 5 Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactio	2005
Association of high-density lipoprotein levels and carotid atherosclerotic plaque characteristics by magnetic resonance imaging. The international journal of cardiovascular imaging, 2007, Volume: 23, Issue:3 Topics: Adult; Atherosclerosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Angiography; Fema	2007
Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. Medical hypotheses, 2007, Volume: 69, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Humans; Hypolipidemic Agents; Lipids; Models, Ca	2007
The continuing complexities of high-density lipoprotein metabolism in drug discovery and development. Expert opinion on therapeutic targets, 2007, Volume: 11, Issue:9 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Prote	2007

Article	Year
Comparative effects of 2.5mg levamlodipine and 5mg amlodipine on vascular endothelial function and atherosclerosis. Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:5(Special) Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atherosclerosis; Endothelium, Vascular	2019
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Niacin Increases Atherogenic Proteins in High-Density Lipoprotein of Statin-Treated Subjects. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:8 Topics: Adult; Atherosclerosis; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylgl	2021
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European journal of clinical investigation, 2013, Volume: 43, Issue:7 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-R	2013
Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial. Stroke, 2013, Volume: 44, Issue:10 Topics: Aged; Atherosclerosis; Brain Ischemia; Delayed-Action Preparations; Female; Follow-Up Studies; Human	2013
Effects of extended-release niacin with laropiprant in high-risk patients. The New England journal of medicine, 2014, Jul-17, Volume: 371, Issue:3 Topics: Aged; Atherosclerosis; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus; Double-Blin	2014
A pilot trial to examine the effect of high-dose niacin on arterial wall inflammation using fluorodeoxyglucose positron emission tomography. Academic radiology, 2015, Volume: 22, Issue:5 Topics: Aorta; Aspirin; Atherosclerosis; Carotid Arteries; Double-Blind Method; Female; Fluorodeoxyglucose F	2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. The Journal of invasive cardiology, 2015, Volume: 27, Issue:10 Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti	2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. The Journal of invasive cardiology, 2015, Volume: 27, Issue:10 Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti	2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. The Journal of invasive cardiology, 2015, Volume: 27, Issue:10 Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti	2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial. The Journal of invasive cardiology, 2015, Volume: 27, Issue:10 Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti	2015
Effect of Extended-Release Niacin on Carotid Intima Media Thickness, Reactive Hyperemia, and Endothelial Progenitor Cell Mobilization: Insights From the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts The Journal of invasive cardiology, 2015, Volume: 27, Issue:12 Topics: Aged; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Coronary Artery Disease; De	2015
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. Journal of the American College of Cardiology, 2010, Jun-15, Volume: 55, Issue:24 Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery, Common; Cholesterol, HD	2010
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vascular health and risk management, 2010, Nov-24, Volume: 6 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Act	2010
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of lipid research, 2011, Volume: 52, Issue:3 Topics: Antioxidants; Apolipoproteins B; Atherosclerosis; Cholesterol; Coronary Angiography; Coronary Stenos	2011
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothro American heart journal, 2011, Volume: 161, Issue:3 Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Ch	2011
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. Kardiologiia, 2011, Volume: 51, Issue:5 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Cor	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England journal of medicine, 2011, Dec-15, Volume: 365, Issue:24 Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL;	2011
Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus. Metabolic syndrome and related disorders, 2012, Volume: 10, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Chy	2012
Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2 Topics: Adult; Aged; Antioxidants; Atherosclerosis; Cytokines; Dietary Supplements; Drug Therapy, Combinatio	2006
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study. American heart journal, 2007, Volume: 154, Issue:2 Topics: Allylamine; Atherosclerosis; Atorvastatin; Carotid Stenosis; Colesevelam Hydrochloride; Double-Blind	2007
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. International journal of clinical practice, 2007, Volume: 61, Issue:11 Topics: Adult; Atherosclerosis; Biomarkers; Blood Glucose; Carotid Arteries; Cholesterol, HDL; Delayed-Actio	2007

niacin and Atherogenesis